米氮平与马普替林治疗抑郁症对照研究

A Comparative Study of Mirtazapine and Maprotiiine in the Treatment of Depression.

目的评价米氮平与马普替林治疗抑郁症的疗效和不良反应。方法将符合CCM D-3诊断标准的60例抑郁症住院和门诊患者,随机平分为两组,分别给予米氮平和马普替林治疗,疗程6周。用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和不良反应。结果米氮平与马普替林治疗抑郁症的疗效接近,但前者起效更快,不良反应少于后者。结论米氮平是一种安全、有效的新一代抗抑郁药,可以作为治疗抑郁症的第一线抗抑郁药使用。

Objective To compare efficacy and side effects between mirtazapine and maprotiline m the treatment ot aepression. Methods 60 inpatients and outpatients with a diagnosis of depression according to CCMD-3 were involved in this study, they were randomly assigned to mirtazapine group （n= 30） and maprotiline group （n=30） for 6 weeks. Effects and side reactions were evaluated with HAMD, HAMA and TESS before and after the treatment. Results Efficacy of mirtazapine was similar to that of maprotiline, however mirtazapine took effect more quickly and is side effects were less than maprotiline. Conclusion Mirtazapine is an effective and safe antidepressant. It suggests that mirtazapine could be used as a first-line antidepressant in the treatment of depression.